Illumina reports Q1 2026 results today after the close, arriving at the print already beaten up — down 7.8% on the week and 5.2% on Wednesday alone, with two consecutive double-digit post-earnings drops in recent memory shaping the backdrop.
The price action this week tells a defensive story. The stock closed at $120.37 on Tuesday, and Wednesday's 5.2% decline dragged it back toward levels last tested in early February. That move came with the Q1 print due the same evening, which adds an unusual twist: the selling arrived ahead of the number, not after. Peers were also under pressure — BRKR fell 5.4% and PACB dropped 7.0% on the day — but TMO declined only 0.8%, suggesting some of Illumina's weakness was stock-specific rather than sector-wide.
The positioning backdrop is notably calm given the circumstances. Short interest has edged higher this week, rising 3.3% over seven days to 4.7% of the free float — a modest rebuild but still well below early April levels when shorts were closer to 5.2% of float before covering sharply around April 10. Borrow remains almost entirely unconstricted: the cost to borrow has drifted up roughly 17% over the past month but still sits below 0.5% annualised, signalling this is routine demand rather than a squeeze dynamic. Availability in the lending market is abundant, with utilisation tracking just 6.6% against a 52-week peak of 13.4% — that means the vast majority of lendable shares remain idle, leaving plenty of room for new short positions without pressure on borrow. Options are equally composed: the put/call ratio is near 0.50, essentially flat with its 20-day average of 0.51, and sits close to the middle of its 52-week range of 0.15–0.75. There is no meaningful hedging surge here.
The Street is split but tilts cautiously optimistic heading into results. The consensus price target runs near $137, roughly 13% above Wednesday's close. Buy-rated analysts point to mid-single-digit growth in clinical consumables, the MiSeq i100 Plus drawing new customers into sequencing, and an earlier EPS guidance raise to $4.45–$4.55 non-GAAP as reasons for optimism. The bear side anchors on harder numbers: Q3 2025 guidance called for a revenue decline of 1.5–2.5% year-on-year, sequencing consumables growth limited to 1–3% ex-China, and a meaningful drop in NovaSeq X shipments versus both the prior quarter and the prior year. Piper Sandler and JP Morgan both cut targets in February following the last earnings release — Piper to $170 and JP Morgan to $120 — while a handful of others raised targets in January before that print. The mean target of ~$137 sits in a wide band between Barclays' $110 underweight and Guggenheim's $170 buy, which sums up the genuine disagreement on trajectory. On valuation, the P/E multiple has compressed about a full turn over the past week to 22.5x, and EV/EBITDA has slipped to 13.6x from 14.5x a month ago — partly price-driven, partly reflecting the week's sell-off.
Institutional ownership is concentrated and relatively steady. Capital Research holds 13.4% of shares, BlackRock 12.1%, and Vanguard 9.5%, with all three adding modestly in Q1. The activist angle has not disappeared: Keith Meister and Corvex Management together hold just over 5% of the company, a position that has been stable in recent filings. The more notable shift in the holder table is Sessa Capital, which trimmed its position by 1.28 million shares in Q4 2025 — the largest directional move among named holders in the data.
The earnings history gives clear context for the risk framing. The February 2026 earnings print sent the stock down 12.2% the next day and 12.6% over the following five days. The event just before that produced a 10.8% single-day decline. The most recent print on April 24 produced a 2.5% gain — the only positive reaction in the series — but that modest bounce has already been fully reversed and then some by this week's pre-print selling. What to watch when the number hits after the close: whether management updates full-year guidance, the trajectory of NovaSeq X placements, and any commentary on China funding and NIH dynamics, the two macro variables the bull case leans most heavily on.
See the live data behind this article on ORTEX.
Open ILMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
